HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action

This article was originally published in The Tan Sheet

Executive Summary

FDA will continue to take actions against dietary supplement products prompted by a lower tolerance for adverse events than for other types of products, a policy reflected in its request for a recall the Hydroxycut weight-loss product line
Advertisement

Related Content

Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA
Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution
FDA Suggests Supplement Firms Use MedDRA Internally For AER Data
FDA Suggests Supplement Firms Use MedDRA Internally For AER Data
Final Guidance For Reporting Adverse Events Gets Serious On Definitions
Final Guidance For Reporting Adverse Events Gets Serious On Definitions
FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market
FDA Expands Acetaminophen, NSAID Labeling Beyond Tentative Final Rule
Adverse Event System Success Will Depend On Trained Reporters, Experts Say

Topics

Advertisement
UsernamePublicRestriction

Register

RS135535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel